AVBP

ArriVent BioPharma, Inc.
CAPPED RATING

ArriVent BioPharma, Inc. (AVBP) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C
Factor Score 2.2 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -61.5%
Price Return 12M -41.3%
Catalyst Signal 0.00
Market Cap $597.9M
TTM Revenue $5.0M
Price / Sales 119.6
ROE -48.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C (2.2) C+ (2.8) C (2.2) D (1.3) C+ (2.6) C (2.2)
2026-11-10 C+ (2.5) C- (2.0) D+ (1.7) D (1.3) C+ (2.6) C- (2.0)
2026-11-03 C+ (2.5) C- (2.0) D+ (1.7) C (2.3) C+ (2.7) C (2.2)
2026-10-27 C+ (2.5) C- (2.0) C- (1.9) C (2.3) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) C- (1.9) C- (1.9) C (2.3) C+ (2.6) C (2.2)
Page 1 of 4